Cempra Inc.'s community acquired bacterial pneumonia (CABP) antibiotic Solithera (solithromycin) barely squeaked passed an FDA advisory panel, but the drug will likely be forced to conduct another clinical trial of the drug regardless of the approval outcome.
The Antimicrobial Drugs Advisory Committee voted 7-6 that the efficacy results of Solithera outweigh its risks, including hepatotoxicity. Panelists previously...




